Identifying a target group for selenium supplementation in high-risk cardiac surgery: a secondary analysis of the SUSTAIN CSX trial.

Quirin NotzDaren K HeylandZheng-Yii LeeJohannes MengerJohannes HerrmannThilo S ChillonStephen FremesSiamak MohammadiGunnar ElkeC David MazerAileen HillMarkus VeltenSascha OttMaren Kleine-BrueggeneyPatrick MeybohmLutz SchomburgChristian Stoppe

Published in: Intensive care medicine experimental (2023)

The identification of GPx3 responders encourages further refined investigations into the treatment effects of selenium in high-risk cardiac surgery patients.

Keyphrases

cardiac surgery
acute kidney injury
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
study protocol
randomized controlled trial
phase ii
patient reported
open label
double blind
placebo controlled